Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Antibody-dependent enhancement (ADE) of viral entry has been observed for many viruses. It was shown that antibodies target one serotype of viruses but only subneutralize another, leading to ADE of the latter viruses. Here we identify a novel mechanism for ADE: a neutralizing antibody binds to the surface spike protein of coronaviruses like a viral receptor, triggers a conformational change of the spike, and mediates viral entry into IgG Fc receptor-expressing cells through canonical viral-receptor-dependent pathways. We further evaluated how antibody dosages impacted viral entry into cells expressing viral receptor, Fc receptor, or both receptors. This study reveals complex roles of antibodies in viral entry and can guide future vaccine design and antibody-based drug therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
Coronavirus as a possible cause of severe acute respiratory syndrome
Peiris, J., Lai, S., Poon, L., Guan, Y., Yam, L., Lim, W., Nicholls, J., Yee, W., Yan, W., Cheung, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13077-2 · Cited by 2,915
Structure, Function, and Evolution of Coronavirus Spike Proteins
Li, F. (2016) · Annual Review of Virology · doi:10.1146/annurev-virology-110615-042301 · Cited by 2,740
Self-citationDipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061 · cited 1×
“5 (ACE2) and dipeptidyl peptidase 4 (DPP4), respectively, as their viral receptor (26-28).”
BackgroundStructure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor
Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005) · Science · doi:10.1126/science.1116480 · Cited by 2,031
Self-citationCoronaviruses post-SARS: update on replication and pathogenesis
Perlman, S., & Netland, J. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2147 · Cited by 1,764
A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics
Uhlén, M., Björling, E., Agaton, C., Szigyarto, C. A.-K., Amini, B., Andersen, E., Andersson, A.-C., Angelidou, P., Asplund, A., Asplund, C., et al. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500279-mcp200 · Cited by 1,540
Cited by
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
“Some antibodies against SARSCoV-1 Spike mediate antibody-dependent enhancement (ADE) of infection in vitro and exacerbate disease in animal models (Jaume et al., 2011; Wan et al., 2020; Wang et al., 2014; Yip et al., 2016).”
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Self-citationSingle-cell landscape of bronchoalveolar immune cells in patients with COVID-19
Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X., Wang, F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0901-9 · Cited by 2,614
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Self-citationViral targets for vaccines against COVID-19
Dai, L., & Gao, G. F. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00480-0 · Cited by 1,048
Aging in COVID-19: Vulnerability, immunity and intervention
Chen, Y., Klein, S. L., Garibaldi, B. T., Li, H., Wu, C., Osevala, N. M., Li, T., Margolick, J. B., Pawelec, G., & Leng, S. X. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101205 · Cited by 1,007
Self-citationAhn, D.-G., Shin, H.-J., Kim, M.-H., Lee, S., Kim, H.-S., Myoung, J., Kim, B.-T., & Kim, S.-J. (2020) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2003.03011 · Cited by 1,001
The convalescent sera option for containing COVID-19
Casadevall, A., & Pirofski, L.-A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138003 · Cited by 903
Deployment of convalescent plasma for the prevention and treatment of COVID-19
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 799
Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity
Shrock, E., Fujimura, E., Kula, T., Timms, R. T., Lee, I.-H., Leng, Y., Robinson, M. L., Sie, B. M., Li, M. Z., Chen, Y., et al. (2020) · Science · doi:10.1126/science.abd4250 · Cited by 678
“surface proteins could increase the risk of severe disease due to antibody-dependent enhancement (ADE), as has been observed for SARS-CoV (16, 17).”
Self-citationImmune response, inflammation, and the clinical spectrum of COVID-19
García, L. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01441 · Cited by 739
Emerging Pandemic Diseases: How We Got to COVID-19
Morens, D. M., & Fauci, A. S. (2020) · Cell · doi:10.1016/j.cell.2020.08.021 · Cited by 716
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00789-5 · Cited by 676
Immune determinants of COVID-19 disease presentation and severity
Brodin, P. (2021) · Nature Medicine · doi:10.1038/s41591-020-01202-8 · Cited by 663
Kang, S., Yang, M., Hong, Z., Zhang, L., Huang, Z., Chen, X., He, S., Zhou, Z., Zhou, Z., Chen, Q., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.009 · Cited by 632
The role of IgG Fc receptors in antibody-dependent enhancement
Bournazos, S., Gupta, A., & Ravetch, J. V. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00410-0 · Cited by 617
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 603
Self-citationA Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
Dai, L., Zheng, T., Xu, K., Han, Y., Xu, L., Huang, E., An, Y., Cheng, Y., Li, S., Liu, M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.035 · Cited by 495
Zoran, M. A., Savastru, R. S., Savastru, D. M., & Tautan, M. N. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.139825 · Cited by 491
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020) · Nature · doi:10.1038/s41586-020-2538-8 · Cited by 485
Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past
Shah, V. K., Firmal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01949 · Cited by 475
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
Joyner, M. J., Wright, R. S., Fairweather, D., Senefeld, J. W., Bruno, K. A., Klassen, S. A., Carter, R. E., Klompas, A. M., Wiggins, C. C., Shepherd, J. R. A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140200 · Cited by 471
Carter, M. J., Fish, M., Jennings, A., Doores, K. J., Wellman, P., Seow, J., Acors, S., Graham, C., Timms, E., Kenny, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1054-6 · Cited by 419
Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
Koenig, P.-A., Das, H., Liu, H., Kümmerer, B. M., Gohr, F. N., Jenster, L.-M., Schiffelers, L. D. J., Tesfamariam, Y. M., Uchima, M., Wuerth, J. D., et al. (2021) · Science · doi:10.1126/science.abe6230 · Cited by 396
Piechotta, V., Chai, K. L., Valk, S. J., Doree, C., Monsef, I., Wood, E. M., Lamikanra, A., Kimber, C., McQuilten, Z., So-Osman, C., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013600.pub2 · Cited by 367
Ma, X., Zou, F., Yu, F., Li, R., Yuan, Y., Zhang, Y., Zhang, X., Deng, J., Chen, T., Song, Z., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.015 · Cited by 342
Self-citationLiang, Y., Wang, M.-L., Chien, C.-S., Yarmishyn, A. A., Yang, Y.-P., Lai, W.-Y., Luo, Y.-H., Lin, Y.-T., Chen, Y.-J., Chang, P.-C., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01022 · Cited by 339
Self-citationNeutralization of SARS-CoV-2 by Destruction of the Prefusion Spike
Huo, J., Zhao, Y., Ren, J., Zhou, D., Duyvesteyn, H. M. E., Ginn, H. M., Carrique, L., Malinauskas, T., Ruza, R. R., Shah, P. N. M., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.010 · Cited by 332
Proinflammatory IgG Fc structures in patients with severe COVID-19
Chakraborty, S., Gonzalez, J., Edwards, K., Mallajosyula, V., Buzzanco, A. S., Sherwood, R., Buffone, C., Kathale, N., Providenza, S., Xie, M. M., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00828-7 · Cited by 326
Emerging treatment strategies for COVID-19 infection
Gavriatopoulou, M., Ntanasis-Stathopoulos, I., Korompoki, E., Fotiou, D., Migkou, M., Tzanninis, I.-G., Psaltopoulou, T., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2021) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00671-y · Cited by 326
A thermostable, closed SARS-CoV-2 spike protein trimer
Xiong, X., Qu, K., Ciazynska, K. A., Hosmillo, M., Carter, A. P., Ebrahimi, S., Ke, Z., Scheres, S. H. W., Bergamaschi, L., Grice, G. L., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0478-5 · Cited by 313
Kruse, R. L. (2020) · F1000Research · doi:10.12688/f1000research.22211.1 · Cited by 311
Grzelak, L., Temmam, S., Planchais, C., Demeret, C., Tondeur, L., Huon, C., Guivel-Benhassine, F., Staropoli, I., Chazal, M., Dufloo, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abc3103 · Cited by 310
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
Lempp, F. A., Soriaga, L. B., Montiel-Ruiz, M., Benigni, F., Noack, J., Park, Y.-J., Bianchi, S., Walls, A. C., Bowen, J. E., Zhou, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03925-1 · Cited by 297
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
Li, D., Edwards, R. J., Manne, K., Martinez, D. R., Schäfer, A., Alam, S. M., Wiehe, K., Lu, X., Parks, R., Sutherland, L. L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.021 · Cited by 287
DNA vaccines against COVID-19: Perspectives and challenges
Silveira, M. M., Moreira, G. M. S. G., & Mendonça, M. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118919 · Cited by 285
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
Liu, Y., Soh, W. T., Kishikawa, J.-I., Hirose, M., Nakayama, E. E., Li, S., Sasai, M., Suzuki, T., Tada, A., Arakawa, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.032 · Cited by 285
Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure
Eyal, N., Lipsitch, M., & Smith, P. G. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa152 · Cited by 282
Prospects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Hesperidin and SARS-CoV-2: New Light on the Healthy Function of Citrus Fruits
Bellavite, P., & Donzelli, A. (2020) · Antioxidants · doi:10.3390/antiox9080742 · Cited by 207
Microstructure, pathophysiology, and potential therapeutics of COVID‐19: A comprehensive review
Singh, S. P., Pritam, M., Pandey, B., & Yadav, T. P. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26254 · Cited by 166
Quinlan, B. D., Mou, H., Zhang, L., Guo, Y., He, W., Ojha, A., Parcells, M. S., Luo, G., Li, W., Zhong, G., et al. (2020) · doi:10.1101/2020.04.10.036418 · Cited by 140
“, 2016), and SARS-CoV-1 ADE has been observed by several groups in cell culture studies (Jaume et al., 2011; Liu et al., 2019; Wan et al., 2020; Wang et al., 2014; Yang et al., 2005; Yip et al., 2014).”
BackgroundKu, M.-W., Bourgine, M., Authié, P., Lopez, J., Nemirov, K., Moncoq, F., Noirat, A., Vesin, B., Nevo, F., Blanc, C., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.12.010 · Cited by 139
Approaches and Challenges in SARS-CoV-2 Vaccine Development
Dagotto, G., Yu, J., & Barouch, D. H. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.08.002 · Cited by 103
“Consistent with this observation, several studies observed enhanced respiratory disease (ERD) in response to SARS vaccines when antibodies had suboptimal potency or low binding affinity (Jaume et al., 2011; Wan et al., 2020; Wang et al., 2014).”
Zang, J., Gu, C., Zhou, B., Zhang, C., Yang, Y., Xu, S., Bai, L., Zhang, R., Deng, Q., Yuan, Z., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-00199-1 · Cited by 67
Metadata
- Authors
- Wan, Y., Shang, J., Sun, S., Tai, W., Chen, J., Geng, Q., He, L., Chen, Y., Wu, J., Shi, Z., Zhou, Y., Du, L., & Li, F.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2020-02-14
- Volume
- 94
- Issue
- 5
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2995449088
- Cited by
- 662
- References
- 64
- FWCI
- 94.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.